Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.

Sipeky C, Llerena A, Manolopoulos VG, Pearson E, Mlakar V, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, Ansari M, Drago F, van Schaik RH.

Pharmacogenomics. 2019 Oct;20(15):1063-1069. doi: 10.2217/pgs-2019-0095.

PMID:
31588876
2.

Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis.

Kodrič K, Zupan J, Kranjc T, Komadina R, Mlakar V, Marc J, Lovšin N.

Exp Mol Med. 2019 Aug 14;51(8):97. doi: 10.1038/s12276-019-0294-3.

PMID:
31409771
3.

The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Golay H, Jurkovic Mlakar S, Mlakar V, Nava T, Ansari M.

Int J Mol Sci. 2019 Aug 9;20(16). pii: E3889. doi: 10.3390/ijms20163889. Review.

4.

4th ESPT summer school: precision medicine and personalised health.

Mlakar V, Marc J, Manolopoulos VG, Cascorbi I, Stanković S, Llerena A, Simmaco M, Visvikis-Siest S, Amstutz U, Sipeky C, Meyer UA, Meier-Abt P, van Schaik RH, Ansari M.

Pharmacogenomics. 2019 May;20(7):471-474. doi: 10.2217/pgs-2019-0008.

5.

Telomerase stability and evaluation of real-time telomeric repeat amplification protocol.

Vukašinović AR, Kotur-Stevuljević JM, Mlakar V, Sopić MD, Cvetković ZP, Petković MR, Spasojević-Kalimanovska VV, Bogavac-Stanojević NB, Ostanek B.

Scand J Clin Lab Invest. 2019 May;79(3):188-193. doi: 10.1080/00365513.2019.1576220. Epub 2019 Feb 15.

PMID:
30767570
6.

PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level.

Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi KS, Maris JM, Ansari M, Gumy-Pause F.

J Exp Clin Cancer Res. 2019 Feb 12;38(1):69. doi: 10.1186/s13046-019-1066-6.

7.

Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis.

Vrtačnik P, Zupan J, Mlakar V, Kranjc T, Marc J, Kern B, Ostanek B.

Sci Rep. 2018 Nov 1;8(1):16215. doi: 10.1038/s41598-018-34255-4.

8.

Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT).

Amstutz U, Mlakar V, Curtis PH, Samer C, Baumann P, Bühlmann RP, Meier-Abt P, Meyer UA, van Schaik RHN, Ansari M; Swiss group of Pharmacogenomics and Personalised Therapy.

Drug Metab Pers Ther. 2017 Dec 20;32(4):173-174. doi: 10.1515/dmpt-2017-0033. No abstract available.

9.

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.

Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt H, Krajinovic M.

Oncotarget. 2017 Aug 27;8(53):90852-90867. doi: 10.18632/oncotarget.20310. eCollection 2017 Oct 31.

10.

The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.

Uppugunduri CRS, Storelli F, Mlakar V, Huezo-Diaz Curtis P, Rezgui A, Théorêt Y, Marino D, Doffey-Lazeyras F, Chalandon Y, Bader P, Daali Y, Bittencourt H, Krajinovic M, Ansari M.

Front Pharmacol. 2017 Jul 11;8:451. doi: 10.3389/fphar.2017.00451. eCollection 2017.

11.

11q deletion in neuroblastoma: a review of biological and clinical implications.

Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F.

Mol Cancer. 2017 Jun 29;16(1):114. doi: 10.1186/s12943-017-0686-8. Review.

12.

8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016.

Visvikis-Siest S, Aldasoro Arguinano AA, Stathopoulou M, Xie T, Petrelis A, Weryha G, Froguel P, Meier-Abt P, Meyer UA, Mlakar V, Ansari M, Papassotiropoulos A, Dedoussis G, Pan B, Bühlmann RP, Noyer-Weidner M, Dietrich PY, Van Schaik R, Innocenti F, März W, Bekris LM, Deloukas P.

Drug Metab Pers Ther. 2017 May 24;32(2):119-127. doi: 10.1515/dmpt-2017-0011. No abstract available.

PMID:
28475488
13.

Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, Krajinovic M, Ansari M.

Int J Mol Sci. 2016 Sep 8;17(9). pii: E1502. doi: 10.3390/ijms17091502. Review.

14.

Genome-wide gene expression profiling of low-dose, long-term exposure of human osteosarcoma cells to bisphenol A and its analogs bisphenols AF and S.

Fic A, Mlakar SJ, Juvan P, Mlakar V, Marc J, Dolenc MS, Broberg K, Mašič LP.

Toxicol In Vitro. 2015 Aug;29(5):1060-9. doi: 10.1016/j.tiv.2015.03.014. Epub 2015 Apr 22.

PMID:
25912373
15.

ADRA2A is involved in neuro-endocrine regulation of bone resorption.

Mlakar V, Jurkovic Mlakar S, Zupan J, Komadina R, Prezelj J, Marc J.

J Cell Mol Med. 2015 Jul;19(7):1520-9. doi: 10.1111/jcmm.12505. Epub 2015 Mar 27.

16.

Preparation of reference material for UGT1A1 (TA)n polymorphism genotyping.

Mlakar V, Mlakar SJ, Marc J, Ostanek B.

Clin Chim Acta. 2014 Aug 5;435:24-8. doi: 10.1016/j.cca.2014.04.018. Epub 2014 Apr 29.

PMID:
24785582
17.

Highlights from the latest pharmacogenomic genome-wide association studies.

Mlakar V, Marc J.

Pharmacogenomics. 2013 Mar;14(4):357-60. doi: 10.2217/pgs.13.17. No abstract available.

PMID:
23438881
18.

Assessment of the tumourigenic and metastatic properties of SK-MEL28 melanoma cells surviving electrochemotherapy with bleomycin.

Todorovic V, Sersa G, Mlakar V, Glavac D, Cemazar M.

Radiol Oncol. 2012 Mar;46(1):32-45. doi: 10.2478/v10019-012-0010-6. Epub 2012 Jan 12.

19.

Metastatic potential of melanoma cells is not affected by electrochemotherapy.

Todorovic V, Sersa G, Mlakar V, Glavac D, Flisar K, Cemazar M.

Melanoma Res. 2011 Jun;21(3):196-205. doi: 10.1097/CMR.0b013e328337abd7.

PMID:
20216102
20.

Oligonucleotide DNA microarray profiling of lung adenocarcinoma revealed significant downregulation and deletions of vasoactive intestinal peptide receptor 1.

Mlakar V, Strazisar M, Sok M, Glavac D.

Cancer Invest. 2010 Jun;28(5):487-94. doi: 10.3109/07357900903476752.

PMID:
20014941
21.
22.

Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.

Mlakar V, Berginc G, Volavsek M, Stor Z, Rems M, Glavac D.

BMC Cancer. 2009 Aug 13;9:282. doi: 10.1186/1471-2407-9-282.

23.

The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).

Strazisar M, Mlakar V, Glavac D.

Cell Mol Biol Lett. 2009;14(3):442-56. doi: 10.2478/s11658-009-0011-7. Epub 2009 Feb 23.

24.

Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.

Strazisar M, Mlakar V, Rott T, Glavac D.

Cancer Invest. 2009 May;27(4):407-16. doi: 10.1080/07357900802427919.

PMID:
19229701
25.

LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.

Strazisar M, Mlakar V, Glavac D.

Lung Cancer. 2009 Jun;64(3):257-62. doi: 10.1016/j.lungcan.2008.09.011. Epub 2008 Nov 12.

PMID:
19008013
26.

DNA microarrays and their use in dermatology.

Mlakar V, Glavac D.

Acta Dermatovenerol Alp Pannonica Adriat. 2007 Mar;16(1):7-12. Review.

27.

Cation-induced transcriptional regulation of the dlt operon of Staphylococcus aureus.

Koprivnjak T, Mlakar V, Swanson L, Fournier B, Peschel A, Weiss JP.

J Bacteriol. 2006 May;188(10):3622-30.

Supplemental Content

Loading ...
Support Center